 Proactive Investors USA & Canada | Cell Therapeutics Announces European Launch Of Pixuvri® For Treatment Of ... The Herald | HeraldOnline.com The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who ... Before Jumping on the Cell Therapeutics (CTIC) Bandwagon (CELG, CTIC ... Cell Therapeutics initiates launch of Pixuvri in Europe |
